<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpan...

<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">REHOVOT, Israel</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">April 2, 2026</span> /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.evogene.com/" target="_blank" rel="nofollow">Evogene Ltd.</a> (NASDAQ<span xmlns="http://www.w3.org/1999/xhtml">:</span> EVGN)(TASE: EVGN) (the &#34;<b xmlns="http://www.w3.org/1999/xhtml">Company</b>&#34;, &#34;<b xmlns="http://www.w3.org/1999/xhtml">Evogene</b>&#34;), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the &#34;<b xmlns="http://www.w3.org/1999/xhtml">Letter</b>&#34;) from the Nasdaq Stock Market LLC (&#34;<b xmlns="http://www.w3.org/1999/xhtml">Nasdaq</b>&#34;), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company&#39;s closing bid price for its ordinary shares has been below $1.00 per share for 30 consecutive business days.</p>
<div xmlns="http://www.w3.org/1999/xhtml" id="prni_dvprnejpg0d79left" dir="ltr" style="width: 100%; text-align: left;"><img xmlns="http://www.w3.org/1999/xhtml" id="prnejpg0d79left" title="Evogene Logo" src="https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg" alt="Evogene Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2814604%2FEvogene_Logo.jpg"></img></div><p xmlns="http://www.w3.org/1999/xhtml"> </p><p xmlns="http://www.w3.org/1999/xhtml">The Nasdaq Stock Market Rules provide the Company a period of 180 calendar days to regain compliance. According to the Letter, the Company has until September 28, 2026, to regain compliance with the minimum bid price requirement. The Company will regain compliance, if at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum period of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance from Nasdaq and this matter will be closed.</p><p xmlns="http://www.w3.org/1999/xhtml">If the Company does not demonstrate compliance prior to the end of the 180-day period ending September 28, 2026, the Nasdaq staff will notify the Company that its ordinary shares will be subject to delisting.</p><p xmlns="http://www.w3.org/1999/xhtml">However, the Company may then be eligible for additional time to regain compliance, of up to a further 180 calendar days, if it meets the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement. To be eligible, the Company will also need to provide further written notice of its intention to cure the deficiency during the second compliance period.</p><p xmlns="http://www.w3.org/1999/xhtml">It is noted that Evogene&#39;s continued listing on Nasdaq remains a key priority for the Company. Should the situation not resolve itself over the above-mentioned timeframe, the Company intends to consider other available options to cure the deficiency and regain compliance with the minimum bid requirement within the compliance period, including potentially approving a reverse stock split, among other alternatives.</p><p xmlns="http://www.w3.org/1999/xhtml">The Letter from Nasdaq has no immediate effect on the Company&#39;s Nasdaq listing or the trading of its ordinary shares on Nasdaq, and during the aforementioned cure period, as may be extended, the Company&#39;s ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol &#34;EVGN&#34;. It is further noted that the Letter from Nasdaq has no bearing on Evogene&#39;s listing on the Tel Aviv Stock Exchange, where its ordinary shares are traded under the ticker symbol &#34;EVGN&#34;.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Evogene Ltd.</b></p><p xmlns="http://www.w3.org/1999/xhtml">Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is <i xmlns="http://www.w3.org/1999/xhtml">ChemPass AI<sup xmlns="http://www.w3.org/1999/xhtml">TM</sup></i>, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. By integrating AI-driven molecular design with experimental validation, ChemPass AI&#x2122; enables the efficient discovery of differentiated small-molecule candidates with improved probability of development success. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.</p><p xmlns="http://www.w3.org/1999/xhtml">For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.evogene.com/" target="_blank" rel="nofollow">www.evogene.com</a>. </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b></p><p xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">This press release contains &#34;forward-looking statements&#34; relating to future events. These statements may be identified by words such as &#34;may,&#34; &#34;could,&#34; &#34;expects,&#34; &#34;hopes,&#34; &#34;intends,&#34; &#34;anticipates,&#34; &#34;plans,&#34; &#34;believes,&#34; &#34;scheduled,&#34; &#34;estimates,&#34; &#34;demonstrates&#34; or words of similar meaning. For example, Evogene has utilized forward-looking statements in this press release when it discusses</i> <i xmlns="http://www.w3.org/1999/xhtml">its ability to regain compliance with Nasdaq&#39;s Listing Qualification requirements including by potentially effecting a reverse stock split</i> <i xmlns="http://www.w3.org/1999/xhtml">to regain compliance with the $1.00 minimum bid price requirement. Actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including, </i>the ongoing  war between Israel and the United States against Iran and its sponsored terrorist group<i xmlns="http://www.w3.org/1999/xhtml">, Hezbollah, as well as those additional risk factors identified </i><i xmlns="http://www.w3.org/1999/xhtml">in Evogene&#39;s reports filed with the applicable securities authority. In addition, Evogene relies, and expects to continue to rely, on third parties to conduct certain activities, such as field-trials and pre-clinical studies, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections or assumptions.</i></p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Evogene Investor Relations Contact:</b></p><p xmlns="http://www.w3.org/1999/xhtml">Email: <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:ir@evogene.com" target="_blank" rel="nofollow">ir@evogene.com</a></p><p xmlns="http://www.w3.org/1999/xhtml">Tel: +972-8-9311901</p><p xmlns="http://www.w3.org/1999/xhtml">Logo - <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LN25838&amp;sd=2026-04-02"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/evogene-reports-receipt-of-nasdaq-minimum-bid-price-notification-302732572.html" target="_blank">https://www.prnewswire.com/news-releases/evogene-reports-receipt-of-nasdaq-minimum-bid-price-notification-302732572.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Evogene</p>

EVGN

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Evogene Faces Nasdaq Compliance Challenge, Must Regain $1 Bid Price

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p xmlns=&quot;http://www.w3.org/1999/xhtml&quot;&gt;&lt;span xmlns=&quot;http://www.w3.org/1999/xhtml&quot; class=&quot;legendSpan...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Evogene Ltd. is notified by Nasdaq of non-compliance due to shares trading below $1.00. The company has until September 28, 2026, to regain compliance, potentially considering options such as a reverse stock split to maintain its listing.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Evogene notifies Nasdaq of non-compliance with minimum bid price.</li><li>Shares traded below $1.00 for 30 consecutive days.</li><li>Company has 180 days to regain compliance by September 28, 2026.</li><li>Evogene may consider reverse stock split to avoid delisting.</li><li>No immediate impact on trading; compliance efforts ongoing.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Nasdaq (NDAQ)</strong>: Notified Evogene of compliance impact; critical for listing status.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This event falls under &#039;Corporate Developments&#039; as it directly affects Evogene&#039;s Nasdaq listing compliance and strategic options.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Failure to regain compliance could lead to delisting by September 2026.</li><li>Possible reverse stock split may stabilize share price if implemented.</li><li>Investors may react negatively to ongoing compliance issues affecting stock confidence.</li><li>Market may closely monitor trading volume for signs of shareholder support.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Evogene received a notification from Nasdaq regarding price non-compliance.</li><li>Shares were below $1.00 for 30 consecutive trading days.</li><li>180-day compliance period ends on September 28, 2026.</li><li>Shares can still trade normally during the compliance period.</li><li>Company may need to notify Nasdaq about compliance intentions for additional time.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should watch for compliance actions; potential volatility expected in upcoming months.</p>
  </section>
</section>


<article>
    <header>
        <h2>Evogene Ltd. Receives Nasdaq Minimum Bid Price Notification</h2>
        <p><strong>REHOVOT, Israel</strong>, April 2, 2026 /PRNewswire/ -- <a href="http://www.evogene.com/" target="_blank" rel="nofollow">Evogene Ltd.</a> (NASDAQ: EVGN) (TASE: EVGN), a leader in computational chemistry focusing on small molecule design for pharmaceuticals and agriculture, has announced that it received a notification from the Nasdaq Stock Market LLC regarding non-compliance with minimum bid price requirements.</p>
    </header>
    
    <section>
        <h3>Details of the Nasdaq Notification</h3>
        <p>Evogene was informed that its ordinary shares have been trading below the required bid price of $1.00 for 30 consecutive business days, thus violating Nasdaq Rule 5550(a)(2). The notification gives the company a grace period of 180 calendar days to meet these requirements, ending on <strong>September 28, 2026</strong>.</p>
        <p>To regain compliance, Evogene must ensure that the closing bid price reaches at least $1.00 for at least ten consecutive business days during this period. If compliance is achieved, the matter will be resolved, and Nasdaq will confirm compliance in writing.</p>
    </section>
    
    <section>
        <h3>Consequences of Non-Compliance</h3>
        <p>If Evogene does not meet the compliance requirements by the end of the 180-day period, it faces potential delisting from Nasdaq. However, the company could still be granted an additional 180-day extension if it meets other listing standards for the Nasdaq Capital Market, apart from the bid price.</p>
        <ul>
            <li>Compliance Deadline: <strong>September 28, 2026</strong></li>
            <li>Required Bid Price: <strong>Minimum of $1.00</strong> for ten consecutive business days</li>
            <li>Potential Delisting: If non-compliance persists past the 180-day grace period</li>
        </ul>
    </section>
    
    <section>
        <h3>Measures to Regain Compliance</h3>
        <p>Evogene has emphasized that maintaining its Nasdaq listing is a top priority. Should the situation not improve within the allotted time, the company may consider alternative strategies for compliance. These include the possibility of a reverse stock split among other options.</p>
        <p>Importantly, the notification has no immediate impact on Evogene's stock listing or trading status, as its ordinary shares will continue to be traded under the symbol <strong>EVGN</strong> during the compliance period.</p>
    </section>
    
    <section>
        <h3>About Evogene Ltd.</h3>
        <p>Evogene Ltd. (NASDAQ/TASE: EVGN) specializes in the computational design of small molecules for the pharmaceutical and agricultural sectors. Its proprietary technology, <em>ChemPass AI™</em>, utilizes advanced AI to innovate small molecule development and enhance the success rate of product candidates.</p>
        <p>Through strategic partnerships and in-house development, Evogene aims to deliver valuable products that meet industry needs by combining scientific innovation with practical applications.</p>
        <p>For further details, please visit <a href="http://www.evogene.com/" target="_blank" rel="nofollow">www.evogene.com</a>.</p>
    </section>
    
    <section>
        <h3>Forward-Looking Statements</h3>
        <p>This press release contains forward-looking statements regarding future events, including Evogene's plans to regain compliance with Nasdaq's listing requirements. These statements involve risks and uncertainties that may cause actual results to differ significantly.</p>
    </section>
    
    <footer>
        <h3>Evogene Investor Relations Contact</h3>
        <p>Email: <a href="mailto:ir@evogene.com" target="_blank" rel="nofollow">ir@evogene.com</a></p>
        <p>Tel: +972-8-9311901</p>
    </footer>
</article>

Evogene Ltd. is notified by Nasdaq of non-compliance due to shares trading below $1.00. The company has until September 28, 2026, to regain compliance, potentially considering options such as a reverse stock split to maintain its listing.

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News